These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21599797)

  • 1. Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime.
    Campo Esquisabel AB; Rodríguez MC; Campo-Sosa AO; Rodríguez C; Martínez-Martínez L
    Clin Microbiol Infect; 2011 Dec; 17(12):1817-22. PubMed ID: 21599797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype.
    Wolter DJ; Black JA; Lister PD; Hanson ND
    J Antimicrob Chemother; 2009 Aug; 64(2):294-300. PubMed ID: 19468029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spread of efflux pump-overexpressing, non-metallo-beta-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with blaVIM endemicity.
    Pournaras S; Maniati M; Spanakis N; Ikonomidis A; Tassios PT; Tsakris A; Legakis NJ; Maniatis AN
    J Antimicrob Chemother; 2005 Oct; 56(4):761-4. PubMed ID: 16115825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
    Castanheira M; Mills JC; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6844-50. PubMed ID: 25182652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.
    Hocquet D; Nordmann P; El Garch F; Cabanne L; Plésiat P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1347-51. PubMed ID: 16569851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa.
    Islam S; Jalal S; Wretlind B
    Clin Microbiol Infect; 2004 Oct; 10(10):877-83. PubMed ID: 15373880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analyses of regulatory genes, mexR, nalC, nalD and mexZ of mexAB-oprM and mexXY operons, in efflux pump hyperexpressing multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Suresh M; Nithya N; Jayasree PR; Vimal KP; Manish Kumar PR
    World J Microbiol Biotechnol; 2018 May; 34(6):83. PubMed ID: 29846800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
    Cabot G; Ocampo-Sosa AA; Tubau F; Macia MD; Rodríguez C; Moya B; Zamorano L; Suárez C; Peña C; Martínez-Martínez L; Oliver A;
    Antimicrob Agents Chemother; 2011 May; 55(5):1906-11. PubMed ID: 21357294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
    APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
    Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efflux pump contribution to multidrug resistance in clinical isolates of Pseudomonas aeruginosa.
    Kiser TH; Obritsch MD; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2010 Jul; 30(7):632-8. PubMed ID: 20575627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase.
    Peña C; Suarez C; Tubau F; Juan C; Moya B; Dominguez MA; Oliver A; Pujol M; Ariza J
    J Clin Microbiol; 2009 Aug; 47(8):2381-7. PubMed ID: 19494059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem susceptibility breakpoint for Pseudomonas aeruginosa strains hyperproducing mexB mRNA.
    Giske CG; Borén C; Wretlind B; Kronvall G
    Clin Microbiol Infect; 2005 Aug; 11(8):662-9. PubMed ID: 16008620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.
    Solé M; Fàbrega A; Cobos-Trigueros N; Zamorano L; Ferrer-Navarro M; Ballesté-Delpierre C; Reustle A; Castro P; Nicolás JM; Oliver A; Martínez JA; Vila J
    J Antimicrob Chemother; 2015 Nov; 70(11):3004-13. PubMed ID: 26260130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of carbapenem resistance in non-metallo-beta-lactamase-producing clinical isolates of Pseudomonas aeruginosa from a Tunisian hospital.
    Hammami S; Ghozzi R; Burghoffer B; Arlet G; Redjeb S
    Pathol Biol (Paris); 2009; 57(7-8):530-5. PubMed ID: 18977099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa.
    Pan YP; Xu YH; Wang ZX; Fang YP; Shen JL
    Arch Microbiol; 2016 Aug; 198(6):565-71. PubMed ID: 27060003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The roles of active efflux system overexpression and outer membrane protein OprD deficiency or loss in carbapenem resistance of Pseudomonas aeruginosa].
    Yi MY; Wang PY; Huang HJ; Liu YC
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(7):457-62. PubMed ID: 16677571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.